share_log

22nd Century Raises $1.68 Million in Regulation A Offering, Amends Senior Secured Credit Facility

22nd Century Raises $1.68 Million in Regulation A Offering, Amends Senior Secured Credit Facility

22世纪在《A类规定》发行中筹集了168万美元,修改了高级担保信贷安排
newsfile ·  08/28 09:10

Mocksville, North Carolina--(Newsfile Corp. - August 28, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company focused on nicotine harm reduction and contract manufacturing, today announced that it has secured an additional $1.68 million in gross proceeds from institutional investors through its Regulation A offering priced at $0.57 and from a separate private placement of common warrants. The Company also entered into an amendment to its existing debentures held by JGB Partners and related entities ("JGB").

北卡罗来纳州莫克斯维尔-(新闻稿 - 2024年8月28日)- 22nd Century Group, Inc. (纳斯达克: XXII) ,一家专注于尼古丁伤害减少和合同制造的烟草产品公司,今天宣布成功完成了另有168万美元的投资,来自机构投资者们通过其定向增发(Regulation A offering)以0.57美元的价格,并通过独立的定向增发来实现。该公司还与JGb Partners和相关实体("JGB")达成了对现有债券的修订。

Under the terms of the amended debenture agreements, JGB suspended provisions of the Debentures requiring 20% of any equity issuances to be paid to the Holders through December 31, 2024. Additionally, JGB will limit its monthly redemption right to not more than 50% of the amounts allowed beginning in August 2024 and through July 2025.

根据修订债券协议的条款,JGb暂停了到2024年12月31日之前支付20%权益发行份额给持有人的规定。此外,JGb将在2024年8月及2025年7月前限制其每月赎回权不超过允许金额的50%。

"Accessing additional capital and amending the repayment terms of our Senior Secured Credit Facility enables 22nd Century Group to remain focused on the continued scaling of our contract manufacturing business, while at the same time reactivating and expanding our FDA authorized VLN reduced nicotine content product line in the markets," said Larry Firestone, Chairman and CEO.

"获取额外资金并修改我们的优先有担保信贷设施的还款条款,使22nd Century Group能够继续专注于扩大我们的合同制造业务,同时激活和扩展我们在市场上的FDA授权的低尼古丁含量产品系列," Larry Firestone,董事长兼首席执行官说道。

About 22nd Century Group, Inc.

关于22世纪集团公司

22nd Century Group, Inc. (NASDAQ: XXII) is an agricultural biotechnology company focused on tobacco harm reduction by offering tobacco products with 95% less nicotine, designed to improve health and wellness by helping smokers smoke less. Backed by comprehensive and extensively patented technologies that regulate nicotine biosynthesis activities in the tobacco plant, the Company has pioneered the development of high-yield, proprietary reduced nicotine content (RNC) tobacco plants and clinically validated RNC cigarette products. The Company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette in December 2021. The Company is a subsequent participating manufacturer under the Master Settlement Agreement ("MSA") and vertically integrated for the production of both its own products and contract manufacturing operations ("CMO"), which consist primarily of branded filtered cigars and conventional cigarettes.

22世纪集团股份有限公司 (NASDAQ: XXII) 是一家农业生物科技公司,专注于通过提供含有95%较少尼古丁的烟草产品以减少烟草危害,并旨在通过帮助吸烟者减少吸烟来改善健康和健康状况。该公司通过对烟草植物中尼古丁生物合成活动进行全面和广泛的专利技术调控,开创了高产量的专有减少尼古丁含量 (RNC) 烟草植物和经过临床验证的 RNC 烟卷产品的研发先河。该公司于2021年12月获得了第一个和唯一授予可燃烟卷的 FDA 修改危险烟草产品 (MRTP) 许可。该公司是大众和康卡斯特诉讼达成的大众和康卡斯特协议的后续参与制造商,与自己的产品和合同制造业务 ("CMO") 垂直整合,其主要由品牌过滤雪茄和传统香烟组成。

Learn more at xxiicentury.com, on X, on LinkedIn, and on YouTube.
Learn more about VLN at tryvln.com.

请访问 xxiicentury.com、X、LinkedIn 和 YouTube 了解更多信息。
了解有关VLN的更多信息,请访问 tryvln.com。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性声明的谨慎说明

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, (iii) our financial and operating performance and (iv) our expectations for our business interruption insurance claim. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 28, 2024, and in the Company's Quarterly Reports filed on May 15, 2024 and August 13, 2024. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

除了历史信息,此新闻稿中包含的所有陈述、预期和假设均为前瞻性陈述,包括但不限于我们全年业务展望。前瞻性陈述通常包含诸如"预计"、"相信"、"考虑"、"继续"、"可能"、"估计"、"期待"、"探索"、"预见"、"目标"、"指导"、"打算"、"可能"、"计划"、"潜在"、"预测"、"初步"、"有可能"、"项目"、"有希望"、"寻求"、"应当"、"将会"、"将要"等表达。前瞻性陈述包括但不限于,关于我们的成本降低措施、关于监管执行的预期(包括我们能否获得新规定的豁免)、关于我们的财务和运营业绩以及关于我们的业务中断保险索赔的预期的陈述。实际结果可能与前瞻性陈述中明确或暗示的结果有实质性差异。可能导致实际结果与前瞻性陈述有实质性差异的重要因素已在公司于 2024 年 3 月 28 日提交的年度报告第 10-k 表中的"风险因素"中阐明,并在公司于 2024 年 5 月 15 日和 2024 年 8 月 13 日提交的季度报告中阐明。本发布中提供的所有信息都是截至本文日期的,并且公司不承担任何义务并且无意更新这些前瞻性陈述,除非法律另有要求。

Investor Relations & Media Contact
Matt Kreps
Investor Relations
22nd Century Group
mkreps@xxiicentury.com
214-597-8200

投资者关系与媒体联系
Matt Kreps
投资者关系
22世纪集团
mkreps@xxiicentury.com
214-597-8200

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发